MAPT and Alzheimer disease: We also included donors with FTLD–tau (n = 5), FTLD-FUS (n = 1), AD with limbic-predominant age-related TDP-43 depositions (LATE) (n = 2) and without (n = 1), donors with ALS due to TDP-43 (ALS-TDP (n = 2)) and neurologically healthy controls (n = 6).